

## Appendix 4C

### Monthly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Papyrus Australia Ltd

**ABN**

63 110 868 409

**Month ended ("current Month")**

October 2025

<b>Consolidated statement of cash flows</b>	<b>Current month \$A'000</b>	<b>Year to date (4 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development		(4)
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs	(18)	(67)
(f) administration and corporate costs	(66)	(281)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		195
1.8 Other (provide details if material)	(28)	(25)
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(112)</b>	<b>(182)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(17)	(144)
(d) investments		
(e) intellectual property		

Consolidated statement of cash flows		Current month \$A'000	Year to date (4 months) \$A'000
2.2	(f) other non-current assets Proceeds from disposal of: (a) entities (b) businesses (c) property, plant and equipment (d) investments (e) intellectual property (f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(17)</b>	<b>(144)</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		262
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	40	100
3.4	Transaction costs related to issues of equity securities or convertible debt securities		(1)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>40</b>	<b>361</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	427	303
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(112)	(182)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(17)	(144)

Consolidated statement of cash flows		Current month \$A'000	Year to date (4 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	40	361
	Adjustment		
4.5	Effect of movement in exchange rates on cash held		
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>338</b>	<b>338</b>

5. Reconciliation of cash and cash equivalents		Current month \$A'000	Previous month \$A'000
at the end of the month (as shown in the consolidated statement of cash flows) to the related items in the accounts			
5.1	Bank balances	338	428
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
<b>5.5</b>	<b>Cash and cash equivalents at end of month (should equal item 4.6 above)</b>	<b>338</b>	<b>428</b>
The bank balance at 5.1 includes \$239k which is held in Egypt by PPY's 100% owned subsidiary PPYM, and the funds are restricted.			

6. Payments to related parties of the entity and their associates		Current month \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	2
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
	<ul style="list-style-type: none"> <li>Payment to VP Rigano &amp; Co Pty Ltd for Company Secretarial services by Vince Rigano as Company Secretary \$2,200</li> </ul>	
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your monthly activity report must include a description of, and an explanation for, such payments.</i></p>		

For personal use only

<b>7. Financing facilities</b>	<b>Total facility amount at month end \$A'000</b>	<b>Amount drawn at period end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	250	0
7.2 Credit standby arrangements		
7.3 Other (please specify)	369	369
7.4 <b>Total financing facilities</b>	619	369
7.5 <b>Unused financing facilities available at month end</b>		250
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after month end, include a note providing details of those facilities as well.	
	<p>The loan facility for \$250k is in place with Ramy Azer. Drawdowns at the board's discretion can be request in tranches of \$50k.</p> <p>Interest is only payable on any drawdown amounts and is calculated by applying the NAB "Usaver savings account or, the 12 months term deposit rates" (whichever is the greater plus a 1% margin.</p> <p>Currently no drawdowns have been made on this facility.</p> <p>The Company has an arrangement with Radium Capital to advance loans based on the R&amp;D undertaken that is eligible under the Australian Government Research and Development Tax Incentive Program (R&amp;DTI). The process for drawdowns requires the company to make an application to Radium Capital which is supported by expenditure incurred. The repayment of the loan drawdowns is repaid following the submission of the Company tax return at year end. The annual interest rate payable on loan drawdowns is 15%.</p> <p>The company has received \$369 from Radium Capital as an R&amp;DTI loan facility based on the additional R&amp;D work completed and expensed YTD.</p>	

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(112)
8.2 Cash and cash equivalents at month end (item 4.6)	338
8.3 Unused finance facilities available at month end (item 7.5)	250
8.4 Total available funding (item 8.2 + item 8.3)	588
8.5 <b>Estimated months of funding available (item 8.4 divided by item 8.1)</b>	5.25

*Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated months of funding available must be included in item 8.5.*

8.6 If item 8.5 is less than 6 months, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: No

Included in the current month net operating cash flows of \$112k is one item considered to be abnormal on the basis that it is not a reoccurring expense.

\$31k of the \$66k administration and corporate cost for the month relates to legal and other costs related to the subsequently discontinued application in the Supreme Court of New South Wales.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes

The company received its FY25 R&DTI refund resulting in a cash inflow of \$90k in the month of November 2025.

The company continually reviews its funding options to ensure that it raises sufficient cash to maintain its operating activities. Based on the success of past capital raising activities it expects that any future capital raising activities will continue to be successful.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes

Based on the success of previous capital raisings, the implementation of the contract to manufacture and supply to TBS (announced 28 August 2025) and progress executing the commercialisation roadmap initiatives.

*Note: where item 8.5 is less than 2 months, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

**NOTE:** The information provided in this Appendix 4c does not include financial information of Papyrus Egypt, as Papyrus Australia has written down the value of its investment to zero at the end of FY25. The impairment does not affect PPY's shareholding interest in PPYEg and EBFC, which remains unchanged.

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 November 2025

Authorised by: By the Board

(Name of body or officer authorising release – see note 4)

## Notes

1. This monthly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past month, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this monthly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this monthly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.